SLC5A1 and diabetes mellitus: The treatment of DM involves medications that block or inhibit therapeutic targets, such as dipeptidyl peptidase IV (DPP-IV), insulin receptor (IR), α-glucosidase, α-amylase, glucose transporter type 2 (GLUT2), and sodium-glucose transport protein (SGLT-1) [7].